Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
Alzheimer s & Dementia (2016) - Comments
pubmed: 26238576  doi: 10.1016/j.jalz.2015.06.1893  issn: 1552-5279  issn: 1552-5260 

Eric R. Siemers, Karen L. Sundell, Christopher Carlson, Michael Case, Gopalan Sethuraman, Hong Liu-Seifert, Sherie A. Dowsett, Michael J. Pontecorvo, Robert A. Dean, Ronald Demattos